Stockscreener 앱 받기
266.11
0.61%
1.61
전일 마감가:
$264.50
열려 있는:
$258.58
하루 거래량:
1.42M
Relative Volume:
0.81
시가총액:
$35.61B
수익:
$4.29B
순이익/손실:
$577.22M
주가수익비율:
63.23
EPS:
4.2086
순현금흐름:
$641.34M
1주 성능:
+12.24%
1개월 성능:
+21.51%
6개월 성능:
-18.70%
1년 성능:
-41.33%
1일 변동 폭
$258.02
$266.85
1주일 범위
$233.33
$271.19
52주 변동 폭
$197.81
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
266.11 | 30.68B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-07 | 재개 | Oppenheimer | Outperform |
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech - ChartMill
ALNY Stock Climbs As Analysts Turn Bullish After ESC Data - StocksToTrade
ALNY Stock Rebounds As Analysts Back RNAi Momentum - timothysykes.com
ALNY Stock Rebounds As Analysts Back RNAi Growth Story - timothysykes.com
Alnylam Pharmaceuticals Inc Stock (ALNY) Moved Up by 7.90% on Sep 2: Facts Behind the Movement - TradingKey
Alnylam Pharmaceuticals gains as investors digest fresh ESC data and upcoming conference appearances - Quiver Quantitative
Alnylam to Webcast Presentations at Upcoming September Investor Conferences - Business Wire
ALNY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $455 - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY) - The Globe and Mail
Expanded RNAi Cardio Data Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY) - simplywall.st
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Exploring a 56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case (ALNY:NASDAQ) - Seeking Alpha
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - finance.yahoo.com
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Alnylam drops as AstraZeneca posts full trial results for failed heart drug - Seeking Alpha
Why Everyone Is Watching Alnylam Pharmaceuticals (ALNY) Today - simplywall.st
ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc. - GlobeNewswire
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 - Business Wire
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with 56.72% Potential Upside - DirectorsTalk Interviews
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - AOL.com
Silvant Capital Management LLC Takes $5.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Wealthfront Advisers LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Wealth LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Biotech Is Booming, But These 2 Stocks Missed the Memo - Sahm
Danske Bank A S Takes $19.43 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Lowered TTR Sales Outlook And Legal Probe Might Change The Case For Investing In Alnylam (ALNY) - simplywall.st
Bragar Eagel & Squire, P.C. is Investigating Alnylam - GlobeNewswire
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to "Strong-Buy" at BMO Capital Markets - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention - ChartMill
Mitsubishi UFJ Asset Management Co. Ltd. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Advisors LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
E Fund Management Co. Ltd. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP - Barchart.com
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - WBOC TV
NASDAQ: ALNY: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into Alnylam Pharmaceuticals, Inc. - NewMediaWire
Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today - Quiver Quantitative
Alnylam initiated an outperform at BMO on RNAi pipeline - Seeking Alpha
BMO Capital Markets Initiates Coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga
BMO initiates Alnylam stock with outperform on ATTR franchise growth By Investing.com - Investing.com Canada
ALNY Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing - AOL.com
ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm - NewMediaWire
ALNY Looks 56.8% Undervalued on GF Value™ - GuruFocus
Familial Amyloid Polyneuropathy Market - Future Market Insights
ALNY Looks 56.7% Undervalued on GF Value™ - GuruFocus
Alnylam Pharmaceuticals (ALNY): Investor Outlook With A 62.82% Potential Upside - DirectorsTalk Interviews
ALNY Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm - The Globe and Mail
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
1.22%
0.13%
자본화:
|
볼륨(24시간):